Belluscura PLC Belluscura Expands its Patent Portfolio
May 19 2022 - 1:02AM
RNS Non-Regulatory
TIDMBELL
Belluscura PLC
19 May 2022
Belluscura PLC
("Belluscura" or the "Company")
Belluscura Expands its Oxygen Enrichment Patent Portfolio
Three New Patents Issue related to Extracorporeal membrane
oxygenation (ECMO), Continuous Positive Airway Pressure (CPAP) and
Replaceable Molecular Sieve Technology
LONDON, U.K. AND PLANO, TX, U.S. (19 May 2022). Belluscura plc
(AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces
that three additional US patents have recently issued, increasing
the number of issued and pending patent applications the Company
owns or exclusively licenses to thirty.
The technology covered by the patents, includes:
-- Extracorporeal membrane oxygenation (ECMO) innovations for
when people who are very ill with conditions of the heart and
lungs, or who are waiting for or recovering from a heart
transplant, require a portable artificial lung;
-- Continuous Positive Airway Pressure (CPAP) innovations, a
type of non-invasive ventilation (NIV) or breathing support,
and;
-- Consumer replaceable molecular sieve technology, used to
remove Nitrogen from ordinary air to produce medical grade
supplemental oxygen.
Robert Rauker, CEO of Belluscura plc, said: "Our pioneering
engineering team continues to develop next generation oxygen
enrichment technology along with our research partner, Separation
Design Group. We see significant expanding future opportunities in
the supplemental oxygen field."
For further information please contact:
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive via Walbrook PR
Officer
Anthony Dyer, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
Relations)
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
558 258
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing
oxygen enrichment technology spanning broad industries and
therapies. Our innovative oxygen technologies are designed with a
global purpose: to create improved health and economic outcomes for
the patients, healthcare providers and insurance organisations.
About Reach announcements
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases such as marketing
messages, corporate and product information into the public domain.
An RNS Regulatory announcement is required to be notified under the
AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFMESAEESEDI
(END) Dow Jones Newswires
May 19, 2022 02:02 ET (06:02 GMT)
Belluscura (LSE:BELL)
Historical Stock Chart
From Apr 2024 to May 2024
Belluscura (LSE:BELL)
Historical Stock Chart
From May 2023 to May 2024